Supriya LifescienceQ4 FY24

Supriya Lifescience Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹620.65P/E: 28.1Market Cap: ₹5.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • The company targets 20%+ annual revenue growth driven by a blended portfolio including existing products, new product launches, and CMO/CDMO activities.
  • Peak revenue from the DSM contract is expected around INR60-70 crores with anticipated 20-25 metric tons supply in FY '25.
  • New product launches in regulated markets, including anaesthetic, anti-diabetic, and anti-anxiety categories, are expected to significantly contribute starting FY '25.
  • CMO/CDMO segment is forecasted to contribute 18-20% of total revenue by FY '27, with Amarnath facility advancing capacity.
  • The oral cancer detection kit is scheduled for launch in ~2 years following clinical trials.
  • Capacity utilization currently at ~86%, with new modules (Amarnath and Module E) commissioning by Q2 FY '25; full-scale production to take 2-3 years.
  • Regulated market share is increasing, stabilizing revenue with diversified product basket mitigating seasonality effects.

See what Supriya Lifescience management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The company is currently debt-free with strong cash positions.
  • They do not utilize any working capital limits except for letters of credit and bank guarantees.
  • No borrowings have been utilized in the last six months.
  • There is no mention of any planned fundraising through debt or equity in the current or near future.
  • The company appears focused on organic growth funded through internal accruals and careful capex planning (INR 100 crores planned for FY25).

See what Supriya Lifescience management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Capex of about INR 100 crores anticipated in FY25, mainly for the Ambernath facility and new Module E.
  • Module E is expected to be commissioned by end of the current month, with commercial production starting by Q2 FY25.
  • Ambernath facility is also scheduled to be ready by Q2 FY25 to expand CMO and CDMO activities.
  • An additional capex of approximately INR 75 crores for Ambernath has already been spent.
  • Debottlenecking activities are ongoing to enhance capacity at the current product basket.
  • The new capacities at Lote will reach around 1020 KL, and Ambernath will add approximately 200 KL.
  • Capex and capacity expansion aim to support the scaling up of CMO/CDMO projects, expecting 18-20% of revenue from these by FY27.

Track Supriya Lifescience — get its next earnings analysis in your feed

How does Supriya Lifescience rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSupriya Lifescience
Rev 2Mar 3

How does Supriya Lifescience rank in Pharmaceuticals & Biotechnology?

Compare Supriya Lifescience against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →